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4.1
MODULATION OF NEURON-RESTRICTIVE SILENCING 
FACTOR EXPRESSION IN LUNG CANCER
T.A.S Baokbah , C Eccleston , J Chen , J.M. Coulson 
Liverpool University, Liverpool, United Kingdom
Small cell lung cancer (SCLC) is characterised by the expression of 
neuronal genes not seen in non-SCLC (NSCLC) or normal lung. The 
full-length neuron-restrictive silencer factor (NRSF) is a transcriptional 
repressor of neuronal genes in non-neuronal cells. We previously identiﬁ  ed 
a splice variant of NRSF that encodes a truncated sNRSF isoform expressed 
only in SCLC, and aimed to determine its function and downstream targets. 
We have shown that the expression of several NRSF-regulated genes 
correlated with that of sNRSF in lung cancer and used reporter constructs 
based on NRSF-regulated promoters, such as arginine vasopressin (AVP), 
as readout for sNRSF function. Mutation of an NRSF binding site reduced 
transcription dependent on the AVP promoter in SCLC by 50% (p<0.005), 
whilst overexpression of sNRSF could activate the AVP promoter in 
NSCLC where it is normally silenced. Interestingly, overexpression of 
sNRSF also resulted in signiﬁ  cantly increased proliferation of NSCLC 
(p<0.05). RNA interference (RNAi) was used to further investigate the role 
of sNRSF. Knockdown in lung cancer cells was optimised using published 
sequences to target other proteins, and ﬁ  ve RNAi sequences targeted to 
NRSF or sNRSF were then designed and evaluated. A SCLC line was 
established that stably expresses EGFP and sNRSF RNAi, preliminary 
RT-PCR and immunocytochemistry show down-regulated NRSF. These 
cells also had a reduced ability to activate an AVP reporter construct.   
Taken together, these data support the role of sNRSF as a transcriptional 
activator that antagonises full-length NRSF, and suggest that it may 
be a key transcriptional regulator in SCLC. We are currently further 
characterising the full proﬁ  le of NRSF splicing in SCLC. Lung cancer 
cells with modulated sNRSF expression will now be used to identify 
novel target genes regulated by sNRSF in lung cancer by microarray 
and proteomic analysis. Identiﬁ  cation of biological relevant genes will 
help us to understand the role of sNRSF and may ultimately provide new 
opportunities for developing detection or treatment strategies.
4.2
STABILITY AND HETEROGENEITY OF EXPRESSION PROFILES 
IN LUNG CANCER SPECIMENS HARVESTED FOLLOWING 
SURGICAL RESECTION
FH Blackhall , M Pintilie , DA Wigle , I Jurisica , MS Tsao 
Canada, Ontario Cancer Institute, Princess Margaret Hospital and 
University of Toronto, Toronto
One of the major concerns in microarray proﬁ  ling studies of clinical
samples is the effect of tissue sampling and RNA extraction on the
resultant data.  We analysed gene expression in lung cancer specimens
that were serially harvested from the tumour and snap-frozen at several
intervals up to 120 minutes after surgical resection. Global gene
expression was proﬁ  led on 1.7K cDNA microarrays, and selected stress
and hypoxia-activated genes were evaluated using realtime RT-PCR.
Remarkably, similar gene expression proﬁ   les were obtained for the
majority of samples regardless of the time that had elapsed between
resection and freezing. Realtime RT-PCR studies showed signiﬁ  cant
heterogeneity in the expression levels of stress and hypoxia-activated
genes in samples obtained from different areas of a tumour specimen
at one time point after resection. The variations between multiple
samplings were signiﬁ  cantly greater than those of elapsed time between
sampling/freezing. 
Overall, samples snap-frozen within 30-60 minutes of surgical resection
are acceptable for gene expression studies; thus, making sampling
and snap-freezing tumour samples in a routine surgical pathology
laboratory setting feasible.  However, sampling and pooling from
multiple sites of each tumour may be necessary for expression proﬁ  ling
studies to overcome the molecular heterogeneity present in tumour
specimens.
4.3
MOLECULAR MECHANISMS OF   PLATINUM (PT) BASED 
CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER 
PATIENTS (NSCLC) USING MICROARRAYS
RD Petty 1, GI Murray 2, K Kerr 2, MC Nicolson 3, JD Bissett 3,
E Collie-Duguid 1
1 Department of Medicine and Therapeutics, University of Aberdeen, 
Aberdeen, United Kingdom, 2 Department of Pathology, University 
of Aberdeen, Aberdeen, United Kingdom, 3 Department of Oncology, 
Aberdeen Royal Inﬁ  rmary, Aberdeen, United Kingdom
Introduction: Improved clinical outcomes will result from a better understanding 
of the molecular mechanisms underlying NSCLC pathogenesis and how these can 
be exploited by systemic therapies. Cell line studies have suggested that cytotoxic 
drugs lead to increased mitochondrial membrane permeability (MMP) and that 
subsequent cell death occurs by caspase independent pathways.
Methods: Tumour and uninvolved adjacent paired tissues from NSCLC patients 
who have received Pt based neoadjuvant chemotherapy have been proﬁ  led using 
Affymetrix HG-U133A GeneChips™). Gene expression data has been validated 
at mRNA and protein expression levels. Data was analysed using Affymetrix 
MASv5.0, MicroDBv3.0, DMTv3.0 and Genespring 6.1.
Results: In  supervised data analysis we have identiﬁ  ed contrasting abnormalities 
in cell death pathways in responding and non-responding tumours. Overall, a 
comprehensive inhibition of all programmed cell death (PCD) pathways (both 
caspase dependent and independent) is seen in non-responding tumours, and 
there is a relative over expression of molecules that decrease MMP. However, in 
responding tumours while the pathways of caspase dependent PCD are blocked, 
the pathways of caspase independent PCD appear to be functional, and there is 
a general down regulation of molecules that decrease MMP and up regulation 
of molecules that increase MMP. Expression of effector non-caspase proteases 
involved in apoptosis-like PCD and their inhibitors is strongly correlated with 
extent of tumour response.
Conclusions: These ﬁ   ndings suggest that the functionality of  caspase 
independent PCD pathways may be a critical factor in determining response to Pt 
based therapy in NSCLC patients. Increased MMP may  be a key event that may 
act as a trigger for an apoptotic-like caspase independent PCD. These pathways 
may provide an important target for novel therapeutics that has not previously 
been extensively investigated. This approach may be broadly applicable in the 
optimisation of targeted and conveintional cytotoxic therapies for solid tumours. 
We are evaluating these pathways in a large series of NSCLC patients using 
immunohistochemistry.
4.4
A MOLECULAR PROFILE THAT PREDICTS RESPONSE TO 
PLATINUM BASED CHEMOTHERAPY IN NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS
RD Petty 1, GI Murray 2, K Kerr 2, MC Nicolson 3, JD Bissett 3,
E Collie-Duguid 1
1 Department of Medicine and Therapeutics, University of Aberdeen, 
Aberdeen, United Kingdom, 2 Department of Pathology, University 
of Aberdeen, Aberdeen, United Kingdom, 3 Departmrnt of Oncology, 
Aberdeen Royal Inﬁ  rmary, Aberdeen, United Kingdom
Introduction:  NSCLC is the most common cause of premature death
from malignant disease in western countries. Improved therapy is needed.
Optimisation of all systemic therapies would occur if it were possible
to predict response. This would facilitate individualisation of treatment
planning.
Methods:  Tumour and uninvolved adjacent paired tissues from NSCLC
patients who have received Pt based neoadjuvant chemotherapy have been
proﬁ   led using Affymetrix HG-U133A GeneChips™). Gene expression
data has been validated at mRNA and protein expression levels. Data
was analysed using Affymetrix MASv5.0, MicroDBv3.0, DMTv3.0 and
Genespring 6.1.
Results: Probability (Welch’s t-test p<0.05) and threshold (>2 fold) ﬁ  ltering
identiﬁ  ed 2 subset of genes  that separated samples into 2 groups  based on
diagnosis (tumour:normal) or tumour response (WHO criteria) respectively,
using unsupervised hierarchal clustering. Response was predicted with
100% accuracy  in ‘leave one out cross validation’ using the KNN algorithm.
This gene set has correctly predicted response in an independent tumour
sample with high predictive strength (p ratio =0.015)  and we are currently
proﬁ  ling more patients to form an independent test set.
Conclusions: In this pilot study we have provided a ‘proof of principle’ that
global gene expression proﬁ  ling can identify a molecular proﬁ  le capable of
predicting response in individual patients with NSCLC. We are currently
investigating the ability of the molecular markers identiﬁ   ed to predict
response to Pt based treatment in pre-therapy specimens from a larger series
of patients (approx. 200) with either early (neoadjuvant therapy) or advanced
disease (palliative therapy) using IHC.  We plan to proceed to prospective
studies of global gene expression proﬁ  ling with the aim of identifying a
molecular proﬁ  le that will allow individualised treatment planning.
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PET-BASED MAPPING OF LYMPH NODE SPREAD IN
NON-SMALL CELL LUNG CANCER (NSCLC)
DB Landau , S Ahmad , M O’Doherty , T Treasure 
Guys & St Thomas’ NHS Trust, London, United Kingdom
Introduction: Numerous studies have shown that PET is more accurate 
than CT at identifying thoracic lymph nodes in NSCLC. The aim of this 
study is to investigate the pattern of mediastinal nodal involvement in 
NSCLC in relation to primary tumour location using PET scanning.
Method: Patients were selected from a database of 1400 patients who 
had PET scans for suspected lung cancer between 2000 and 2002. 
Tumour position and site of any lymph node metastases were noted. 
Nodes were considered positive if the Standardised Uptake Value 
(SUV) was signiﬁ  cantly raised relative to the surrounding region.
Results: 288 patients out of 513 were node positive on PET. Of 242 
upper zone (UZ), 126 midzone (MZ) and 145 lower zone(LZ) tumours, 
46%, 40% and 45% respectively were ipsilateral hilar node positive 
(IHN+), 8%, 5% and 20% respectively were subcarinal node (SCN) 
positive and 7%, 4% and 2% respectively were tracheobronchial node 
(TBN) positive. In IHN+ patients 14%, 6% and 23% respectively of 
UZ, MZ and LZ tumours showed increased activity in the SCN, 11%, 
6% and 5% in the TBN and 17%, 7% and 14% in the contralateral hilar 
nodes (CHN). In IHN negative patients the corresponding ﬁ  gures were 
18%, 27% and 70% for SCN, 14%, 18% and 0% for TBN and 21%, 
18% and 10% for CHN. 
Conclusions: IHN involvement is similar regardless of primary tumour 
location. SCN involvement is more common with LZ tumours. TBN 
involvement is more common with UZ tumours. The CHN are more 
commonly involved than other nodal areas more frequently sampled in 
routine clinical practice. The clinical implication of this ﬁ  nding is that 
some patients are signiﬁ  cantly undertreated. The TBN and SCN groups 
may represent 2nd station nodes of distinct lymphatic pathways from IH 
nodes. These results give valuable information for further research into 
patterns of nodal spread in NSCLC aimed at improving radiotherapy 
and surgical planning.
4.6
RESPIRATORY MOTION MODELLING FOR OPTIMISATION OF 
NON-SMALL CELL LUNG CANCER (NSCLC) RADIOTHERAPY
S Ahmad 1, DB Landau 1, JM Blackall 2, M Miquel 2, DJ Hawkes 2
1 Guy’s & St. Thomas’ NHS Trust, London, United Kingdom, 2 King’s 
College London, London, United Kingdom
Introduction:  Despite recent improvements in NSCLC treatment,
respiratory motion signiﬁ  cantly impacts on radiotherapy planning. We are
developing a system to model respiratory motion by investigating complex
3D lung motion and deformation in 10 healthy volunteers and patients with
lung cancer, to create subject-speciﬁ  c models using a novel MR and CT
based imaging and non-rigid registration method.
Method: Models were constructed using a voxel-based image registration
technique to coregister MR images acquired throughout the breathing
cycle. A high-quality reference image, acquired at exhale, was aligned to
each of a sequence of scans at positions between exhale and inhale. Two
different image acquisition techniques were used: 1. free breathing and 2.
at various breath-hold positions between exhale and inhale. Positions of all
points on the surface of the lung were plotted against diaphragm position,
chosen to represent position in the respiratory cycle. Studies were made
of different models to analyse inhale and exhale trajectories of breathing.
Data from selected areas in the lung were investigated to demonstrate
differential lung movement.
Results: Maximum displacement of 16mm, at maximal inhale was
observed when comparing inhale to exhale data. Comparison of two
breathing cycles showed 19mm displacement, at mid-cycle position.
Disproportionately large displacements of up to 27mm were seen when
comparing free breathing to breath-hold models. Diaphragm-adjacent lung
was most mobile (42mm displacement) especially in the superior-inferior
direction. However, up to 10mm lateral movement also occurred at the
lung apex.
Conclusions: Our results suggest that inter-cycle variation may be greater
than intra-cycle variation and that breath-hold models do not accurately
represent lung motion when the subject is breathing freely, as they would
be during radiotherapy treatment. We believe that modelling technology
has the potential to be used for optimisation of radiation delivery and to
further develop 4D radiotherapy planning.
4.7
THE TIMING OF THORACIC IRRADIATION IN LIMITED 
DISEASE SMALL CELL LUNG CANCER
L. E. James 1, A. Hackshaw 1, S. G. Spiro 1, R. M. Rudd 2, P. Clarke 1, 
C. Trask 3, N. H. Gower 1, P. G. Harper 1, R. S. Souhami 1
1 United Kingdom, University College, London, 2 United Kingdom, 
St. Bartholomew’s Hospital, London, 3 United Kingdom, Southend 
Hospital, Essex, 4 United Kingdom, Guy’s Hospital, London
Uncertainty about the optimal timing of thoracic irradiation (TI) led us to 
undertake a randomised trial comparing survival in patients given ‘early’ TI 
(with the 2nd cycle of chemotherapy) with those given ‘late’ TI (with the 6th 
cycle of chemotherapy). Our trial aimed to replicate that of an NCIC study (JCO 
1993,Vol 11 (2): 336) in which early TI increased 3-year survival by 10%.
Between January 1993 and January 2002, 325 patients were randomised to 
receive either early TI or late TI. All patients received chemotherapy, which 
was given every 21 days for 6 courses and consisted of cyclophosphamide, 
doxorubicin and vincristine, alternating with cisplatin and etoposide.  Thoracic 
radiotherapy dose was 40Gy in 15 fractions over 3 weeks. Prophylactic cranial 
radiotherapy, 25Gy in 10 fractions over 2 weeks, was given to responding 
patients with a negative, post treatment, brain scan.
Survival at 3 years was similar between the two arms; 16% in those who received 
early TI and 20% in those who received late TI (hazard ratio 1.18, 95% CI 0.93-
1.51, p=0.18). This is in contrast to the NCIC trial. We therefore looked at other 
trials on the topic:
Trial No. of 
patients
Difference in median
survival (early - late),
% who completed ssigned 
chemo course
months Early Late
Murray 1993 308 +5.2 (p=0.01) 83 84
Jeremic 1997 103 +8.0 (p=0.05)  Similar in 2 arms
Takada 2002 228 +7.5 (p=0.10) 86 88
Perry 1987 270 -1.5 (p=0.08)  Lower in early arm
Work 1997 200 -1.5 (p=0.41) 52 72
Current trial 325 -1.6 (p=0.18) 69 80
Three trials showed that early TI was better and 3 trials showed no difference 
(or early TI slightly worse).  The difference in results seem to be associated with 
chemotherapy uptake. Early TI may only be better if the assigned chemotherapy 
regimen is maintained and not reduced.
4.8
GEFITINIB (‘IRESSA’, ZD1839) IN PATIENTS WITH
NON-SMALL CELL LUNG CANCER (NSCLC): THE ROYAL 
MARSDEN EXPERIENCE
NR Maisey , M Parton , C Harper-Wynne , K Sumpter , S Ashley ,
T Eisen , M O’Brien 
Royal Marsden Hospital, London, United Kingdom
Background: Geﬁ  tinib, an inhibitor of the intracellular tyrosine kinase
domain, has demonstrated useful activity in advanced pre-treated NSCLC
(IDEAL I / II). The clinical efﬁ  cacy of geﬁ  tinib was assessed as part of an
Expanded Access Programme.   
Methods: Patients (pts) were treated with geﬁ  tinib 250mg/day. Endpoints
included overall survival (OS) and time to treatment failure (TTF). Objective
and symptom responses (OR, SR) were assessed at 1 month intervals.
Results:  141 pts were assessed: median age 65 (35-88); male/female,
81/60; performance status (PS) 0/1/2/3, 1/45/39/16%; advanced disease
(IIIB/IV), 123pts; median number of prior chemotherapy regimens, 1 (0-
4). 125 pts were evaluable for OR: partial response (PR) 6%; stable disease
(SD) 55%; progressive disease (PD) 39%. Median duration of disease
control (PR + SD) 13 weeks (95% CI 9-17). 131 pts were evaluable for
SR: symptom improvement (SI) 31%; No change (NC) 33%; worsening
symptoms (WS) 37%. Median duration of symptom control (SI+NC) 11
weeks (95% CI 9-13). The most common toxicity was diarrhoea (Grade
3: 4.5%; Grade IV: 1%). 1 pt died of suspected pneumonitis. Median
OS/TTF 20 weeks (95% CI 13-28) / 8 weeks (95% CI 7-10) respectively.
Pts (n=12) with bronchoalveolar adenocarcinoma (BAC) had signiﬁ  cantly
longer TTF than other histological subtypes (median duration 13 and 8
weeks respectively, p=0.04). OR/SR for pts with BAC was 8.3% / 50%
respectively. Pts with PS3 had signiﬁ  cantly lower OS / TTF (9 and 5 weeks
respectively). OR / SR was 0% / 13.3% respectively. Number of prior
chemotherapy regimens did not signiﬁ  cantly alter OS / TTF.
Conclusions: This series of patients shows similar survival/symptom
response to published phase II data. BAC pts appear to beneﬁ  t more than
other subtypes. Despite low toxicity, geﬁ  tinib does not beneﬁ  t those with
poor PS but can beneﬁ  t heavily pre-treated patients, since the number of
prior chemotherapy regimens did not inﬂ  uence survival. 
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